Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)

Abstract Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have substantially improved anticoagulation therapy for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). The available routine care data have demonstrated the safety of different NOACs...

Full description

Bibliographic Details
Main Authors: Raffaele De Caterina, Peter Kelly, Pedro Monteiro, Jean Claude Deharo, Carlo de Asmundis, Esteban López-de-Sá, Thomas W. Weiss, Johannes Waltenberger, Jan Steffel, Joris R. de Groot, Pierre Levy, Ameet Bakhai, Wolfgang Zierhut, Petra Laeis, Michael Kerschnitzki, Paul-Egbert Reimitz, Paulus Kirchhof, on behalf of the ETNA-AF-Europe investigators
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Cardiovascular Disorders
Subjects:
Non-vitamin K antagonist oral anticoagulants
Real-world
Registry
Stroke prevention
Major bleeding
Safety outcomes
Online Access:http://link.springer.com/article/10.1186/s12872-019-1144-x

Internet

http://link.springer.com/article/10.1186/s12872-019-1144-x

Similar Items